Published in Biomed Res Int on June 11, 2014
Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future. Vaccines (Basel) (2014) 1.01
Pseudotype-based neutralization assays for influenza: a systematic analysis. Front Immunol (2015) 0.88
Changes in heterosubtypic antibody responses during the first year of the 2009 A(H1N1) influenza pandemic. Sci Rep (2016) 0.80
Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol (2009) 12.13
Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol (1999) 11.94
Antibody recognition of a highly conserved influenza virus epitope. Science (2009) 11.26
A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science (2011) 7.86
Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis (2008) 5.69
A highly conserved neutralizing epitope on group 2 influenza A viruses. Science (2011) 5.66
Correlates of protection induced by vaccination. Clin Vaccine Immunol (2010) 5.21
Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest (2010) 4.62
INDUCTION OF PARTIAL SPECIFIC HETEROTYPIC IMMUNITY IN MICE BY A SINGLE INFECTION WITH INFLUENZA A VIRUS. J Bacteriol (1965) 4.12
Comparison of influenza serological techniques by international collaborative study. Vaccine (1994) 2.55
Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis (2011) 2.12
Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol (2013) 2.09
Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J Virol (2012) 2.07
A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza Other Respir Viruses (2007) 1.92
Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? Virus Res (2004) 1.90
Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine (2007) 1.89
Antigenic structure of the haemagglutinin of human influenza A/H2N2 virus. J Gen Virol (2001) 1.71
Immune responses to influenza virus infection. Virus Res (2011) 1.70
The specificity of the anti-haemagglutinin antibody response induced in man by inactivated influenza vaccines and by natural infection. J Hyg (Lond) (1979) 1.65
Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in U.S. populations. J Clin Microbiol (2011) 1.62
Development of subtype-specific and heterosubtypic antibodies to the influenza A virus hemagglutinin after primary infection in children. J Clin Microbiol (1985) 1.59
FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007. Vaccine (2008) 1.55
Interpretation of responses and protective levels of antibody against attenuated influenza A viruses using single radial haemolysis. J Hyg (Lond) (1984) 1.49
Heterotypic immunity to influenza in ferrets. Infect Immun (1980) 1.47
Influenza: global surveillance for epidemic and pandemic variants. Eur J Epidemiol (1994) 1.46
Failure to detect hemagglutination-inhibiting antibodies with intact avian influenza virions. Infect Immun (1982) 1.43
Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One (2010) 1.40
Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. J Virol Methods (2008) 1.39
Structural basis of influenza virus neutralization. Ann N Y Acad Sci (2011) 1.37
Serological evidence of human infections with avian influenza viruses. Brief report. Arch Virol (1986) 1.37
Respiratory and systemic humoral and cellular immune responses of pigs to a heterosubtypic influenza A virus infection. J Gen Virol (2001) 1.30
Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis (2008) 1.28
Heterosubtype neutralizing responses to influenza A (H5N1) viruses are mediated by antibodies to virus haemagglutinin. PLoS One (2009) 1.20
Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses. Vaccine (2009) 1.19
Vaccine-induced antibodies to heterologous influenza A H1N1 viruses: effects of aging and "original antigenic sin". J Infect Dis (1994) 1.09
Optimization and evaluation of an influenza A (H5) pseudotyped lentiviral particle-based serological assay. J Clin Virol (2009) 1.08
Highly conserved sequences for human neutralization epitope on hemagglutinin of influenza A viruses H3N2, H1N1 and H5N1: Implication for human monoclonal antibody recognition. Biochem Biophys Res Commun (2010) 1.08
The production and development of H7 Influenza virus pseudotypes for the study of humoral responses against avian viruses. J Mol Genet Med (2013) 1.03
Evaluation of the single radial hemolysis test for measuring hemagglutinin- and neuraminidase-specific antibodies to H3N2 influenza strains and antibodies to influenza B. J Clin Microbiol (1977) 0.98
Cross-reaction but no avidity change of the serum antibody response after influenza vaccination. Vaccine (1995) 0.96
Collaborative study on influenza vaccine clinical trial serology - part 2: reproducibility study. Pharmeur Bio Sci Notes (2011) 0.91
Vaccines for pandemic influenza: summary of recent clinical trials. Curr Top Microbiol Immunol (2009) 0.89
Pre-existing immunity with high neutralizing activity to 2009 pandemic H1N1 influenza virus in Shanghai population. PLoS One (2013) 0.88
The effect of age and recent influenza vaccination history on the immunogenicity and efficacy of 2009-10 seasonal trivalent inactivated influenza vaccination in children. PLoS One (2013) 0.88
Antibodies against conserved antigens provide opportunities for reform in influenza vaccine design. Front Immunol (2011) 0.85
Comparative serological assays for the study of h5 and h7 avian influenza viruses. Influenza Res Treat (2013) 0.80
Multiplex evaluation of influenza neutralizing antibodies with potential applicability to in-field serological studies. J Immunol Res (2014) 0.91
The Use of Hyperimmune Chicken Reference Sera Is Not Appropriate for the Validation of Influenza Pseudotype Neutralization Assays. Pathogens (2017) 0.75
Evaluation of a Pseudotyped Virus Neutralisation Test for the Measurement of Equine Influenza Virus-Neutralising Antibody Responses Induced by Vaccination and Infection. Vaccines (Basel) (2020) 0.75